https://www.live-feeds.com/feed/fda-approves-updated-covid-19-vaccinesContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/fda-approves-updated-covid-19-vaccineshttps://www.live-feeds.com/feed/fda-approves-updated-covid-19-vaccines#u54039Tue, 01 Sep 2026 13:26:54 +0000The FDA has approved updated COVID-19 vaccines for the 2026-2027 season to target the dominant XFG variant. Approved products include Spikevax and mNEXSPIKE from Moderna, Nuvaxovid from Sanofi, and formulations from Pfizer-BioNTech. Current approvals focus on adults 65 and older and those with underlying health conditions. While case numbers are climbing in areas like Kansas City and Bexar County, they remain below levels seen in previous years. Mayo Clinic issued guidance on August 28 regarding who should receive the updated doses this fall.Why it mattersThese updates coincide with students r https://www.live-feeds.com/feed/fda-approves-updated-covid-19-vaccineshttps://www.live-feeds.com/feed/fda-approves-updated-covid-19-vaccines#u52509Sun, 30 Aug 2026 14:45:26 +0000The FDA approved updated COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax-Sanofi to combat the XFG Stratus variant. Moderna's approved products include Spikevax and mNEXSPIKE, while Sanofi's approved vaccine is Nuvaxovid. Current approvals target adults 65 and older and individuals with underlying health conditions. These approvals come as COVID-19 cases rise in areas like Bexar County, coinciding with students returning to school. Manufacturers are shipping doses to hospitals and pharmacies, though insurance coverage for low-risk individuals remains uncertain.Why it matt https://www.live-feeds.com/feed/fda-approves-updated-covid-19-vaccineshttps://www.live-feeds.com/feed/fda-approves-updated-covid-19-vaccines#u51534Sat, 29 Aug 2026 08:41:01 +0000The FDA has approved updated Covid-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax-Sanofi for the 2026-27 season to target the dominant XFG Stratus variant. The decision allows manufacturers to begin shipping doses, which are expected to arrive at pharmacies and hospitals within days. Current approvals specifically cover adults aged 65 and older and younger individuals with underlying health conditions. While the shots target the latest strain as cases rise, uncertainty remains regarding insurance coverage for those who do not fall into these high-risk categories.Why it mattersThese upd